Attribution You Can Underwrite

The attribution problem payers face

Health plans, Medicare Advantage organizations, KCEs, IPAs, and risk-bearing ACOs all share the same constraint: clinical interventions reduce utilization, but proving which interventions drive which outcomes is structurally difficult. Most vendor relationships are built on self-reported activity, not on a defensible causal chain back to cost and quality impact.

Without that chain, value-based contracting stalls. Shared savings arrangements become negotiation exercises rather than underwriting exercises. And the clinical partners who could credibly reduce cost get evaluated by the same heuristics as the ones who cannot.

On the payer-provider relationship, the friction is structural. Both parties operate without a shared evidence layer, so they end up arguing about drivers neither side can fully verify. Payers want data transparency. Providers want to deliver better care and receive fair reimbursement tied to its quality. Both objectives are reasonable. Both fail in the absence of verifiable outcomes attribution. EPO produces that attribution and gives payers and providers a common evidence base to operate from.

Who this is for

• Medicare Advantage plans building out the clinical infrastructure behind Stars, HEDIS, and total cost of care performance
• Kidney Care Entities (KCEs) and ESCOs managing the medication-heavy complexity of ESRD and late-stage CKD populations
• Risk-bearing ACOs and IPAs entering or expanding downside-risk arrangements where medication-related utilization is a major cost driver
• Commercial risk arrangements where attribution credibility is the bottleneck to scaling shared savings